Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel
NASDAQ:HSCS

HeartSciences Q2 2026 Earnings Report

HeartSciences logo
$2.04 -0.03 (-1.45%)
Closing price 06/3/2026 03:59 PM Eastern
Extended Trading
$1.97 -0.07 (-3.43%)
As of 06/3/2026 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

HeartSciences EPS Results

Actual EPS
-$0.85
Consensus EPS
-$0.90
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

HeartSciences Revenue Results

Actual Revenue
$2.42 million
Expected Revenue
$0.00 million
Beat/Miss
Beat by +$2.42 million
YoY Revenue Growth
N/A

HeartSciences Announcement Details

Quarter
Q2 2026
Date
12/15/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

HeartSciences' next earnings date is estimated for Thursday, July 23, 2026, based on past reporting schedules.

Conference Call Resources

HeartSciences Earnings Headlines

HeartSciences (NASDAQ:HSCS) Trading Down 1.4% - Time to Sell?
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30817806
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
June 2 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305156/0/en/heartsciences-launches-myovista-insights-version-1-3-with-ai-ecg-algorithm-marketplace-and-first-fda-cleared-algorithm.html
Read this warning immediately
Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
 |  Porter & Company (Ad)
HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297483/0/en/heartsciences-signs-commercial-agreement-with-north-shore-health-the-first-hospital-deployment-from-the-cibolo-health-network.html
HeartSciences Stockholders Approve Director Election and Equity Plan
May 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/heartsciences-stockholders-approve-director-election-and-equity-plan?utm_source=marketbeat.com&utm_medium=referral
HeartSciences Inc.: HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights
May 5, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68399060-heartsciences-inc-heartsciences-signs-first-saas-revenues-agreement-following-full-launch-of-myovista-insights-399.htm
See More HeartSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email.

About HeartSciences

HeartSciences (NASDAQ:HSCS), Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms.

Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.

View HeartSciences Profile
Earnings Tools